Compare XPEL & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEL | ODTX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2019 | 2025 |
| Metric | XPEL | ODTX |
|---|---|---|
| Price | $43.80 | $20.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $56.00 | N/A |
| AVG Volume (30 Days) | 153.0K | ★ 246.1K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $476,200,000.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $11.98 | N/A |
| P/E Ratio | $42.48 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $31.87 | $15.10 |
| 52 Week High | $55.91 | $29.05 |
| Indicator | XPEL | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.16 | 40.60 |
| Support Level | $40.19 | $15.10 |
| Resistance Level | $46.71 | $27.62 |
| Average True Range (ATR) | 1.46 | 2.21 |
| MACD | -0.50 | -0.67 |
| Stochastic Oscillator | 8.60 | 16.25 |
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.